Core Viewpoint - The article discusses the 2026 Regional Joint Fund (Beijing) project guidelines, focusing on key industries in Haidian District and Beijing Economic-Technological Development Area, with specific funding allocations for integrated and key projects [1][8]. Group 1: Key Areas of Focus - The guidelines emphasize several key areas for funding, including: - Electronic Information: Integrated circuits, artificial intelligence, wireless communication, and quantum information [2][3]. - Life and Health: Synthetic biology manufacturing, cell and gene therapy, brain science, biomedical engineering, and smart healthcare [3]. - New Materials and Advanced Manufacturing: Robotics, new materials, and intelligent equipment [3]. - Modern Transportation and Aerospace: New energy and intelligent connected vehicles, and aerospace industry [3]. Group 2: Guidelines Requirements - The guidelines require that the proposed needs must meet specific criteria: - Scientific focus on fundamental scientific issues behind technological challenges, avoiding mere technical applications [4]. - Inclusivity without overly restrictive elements, ensuring a balance between specificity and broad applicability [5]. - Directionality that aligns closely with the development needs of Haidian District and Beijing Economic-Technological Development Area [5]. - Safety compliance with national laws and ethical standards, emphasizing the prevention of biological and information security risks [6]. - Innovation to avoid duplication with existing guidelines from national and municipal science funds [6]. Group 3: Submission Requirements - Proposers must meet certain conditions: - The proposing unit must be a supporting unit of the Beijing Natural Science Foundation [7]. - Experience in leading key national science fund projects is required [8]. - Each proposer can submit only one guideline request, and each company can participate in up to two requests [8].

Core Insights - The establishment of Hefei Ian Biotechnology Co., Ltd. with a registered capital of 10 million yuan focuses on the manufacturing and research of bio-based materials, indicating a growing interest in sustainable materials in the industry [1][3]. Group 1: Company Overview - Enhe Biotechnology, founded in 2019 and headquartered in Hangzhou, has become a prominent player in the capital market, utilizing a high-throughput experimental platform to optimize biological engineering for industrial applications [3][4]. - The company has completed over $145 million in financing by 2025 and was recognized as one of the "50 Smartest Companies" by MIT Technology Review in 2020 [4]. Group 2: Strategic Collaborations - In May 2023, a strategic partnership was formed between domestic beauty giant Proya and Enhe Biotechnology, focusing on AI-driven bio-manufacturing technologies for cosmetic ingredient development [5][7]. - This collaboration aims to innovate in the realm of bioactive ingredients for cosmetics, promoting a shift towards efficiency, safety, and sustainability in the beauty industry [7]. Group 3: Industry Movements - Yili Group, a leading dairy company in China, is venturing into synthetic biology, seeking investment opportunities in early-stage innovative companies within the health food sector [8][10]. - Yili has established a venture capital fund with a total subscription amount of 20 million yuan, focusing on high-tech innovations in the health sector, particularly in food science and life sciences [10][11]. Group 4: Sustainability Initiatives - Yili has been actively pursuing sustainable development, as evidenced by its collaboration with Xampla to test a new plant-based packaging material aimed at preserving nutrients in dairy products [12][15]. - The company emphasizes a commitment to a sustainable future while achieving steady business growth [15]. Group 5: Upcoming Events - The 2025 Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on AI and bio-manufacturing, green chemicals, new materials, future food, and agriculture [17][19]. - The conference will feature various activities, including forums, discussions, and showcases of synthetic biology innovations [17][18].

Core Insights - The article highlights the advancements in synthetic biology, particularly through gene editing technologies, which are revolutionizing the production of valuable metabolites and agricultural products, significantly impacting industries such as medicine and agriculture [1][2][5]. Group 1: Synthetic Biology and Gene Editing - The use of genetically engineered yeast to produce artemisinin has demonstrated the potential to replace the extraction from 50,000 acres of Artemisia annua cultivation, benefiting millions of malaria patients in developing countries since 2013 [1]. - Beijing Qihe Biotechnology Co., a representative company in the synthetic biology sector, has achieved a significant increase in oil content in soybeans from over 20% to above 80% through precise gene editing [2]. - The gene editing technology allows for rapid breeding cycles, reducing the time needed to develop disease-resistant traits in crops like wheat from decades to approximately three months [2][3]. Group 2: Innovation Centers and Industrialization - The Beijing Synthetic Biology Manufacturing Technology Innovation Center, established by the local government and Beijing University of Chemical Technology, serves as a core platform for technological innovation in the synthetic biology industry [4]. - The center focuses on comprehensive technological breakthroughs across the entire biological manufacturing value chain, with five research teams already operational [4][6]. - The shift from traditional petrochemical methods to biological production of materials like adipic acid is highlighted as a key step towards a greener, more sustainable industry, with significant reductions in greenhouse gas emissions [4][5]. Group 3: Industry Growth and Future Prospects - The synthetic biology sector is projected to create an economic value of $30 trillion, with an expected global production scale reaching $2 trillion to $4 trillion by 2030 [7]. - The Changping District has established a cluster of over 120 synthetic biology manufacturing companies, with projected revenues exceeding 6 billion yuan in 2024 and significant investments in fixed assets [8]. - Recent policy measures in Changping aim to support the high-quality development of the synthetic biology industry, emphasizing integrated policies and collaborative efforts across the sector [7][8].

Core Viewpoint - Changde City has passed the "Regulations on Promoting the Development of Synthetic Biology Manufacturing Industry," marking the first local legislation in China for this sector, aimed at enhancing the development of synthetic biology manufacturing as a strategic emerging industry [1][2]. Summary by Sections Legislative Background - The "Regulations" are part of a broader initiative to support the high-quality development of the synthetic biology manufacturing industry in Changde, which has been recognized as a key area for new productive forces and strategic emerging industries [2][4]. Industry Development Measures - In February, the Hunan Provincial Government issued measures to support Changde's synthetic biology manufacturing, focusing on areas such as enzyme preparations, pharmaceutical intermediates, agricultural chemicals, future foods, health products, and bio-based materials [4]. Legislative Process - The legislative project for promoting synthetic biology manufacturing began in September 2024, with multiple reviews and revisions leading to the final draft of the "Regulations," which consists of 19 articles addressing various aspects of industry development [5][6]. Key Provisions of the Regulations - The first three articles outline the legislative purpose, scope, and responsibilities of government departments. Articles four to fifteen focus on core industry development issues, including enhancing investment attraction, R&D capabilities, and talent acquisition, while also addressing high operational costs and approval efficiency [6]. - Article sixteen introduces a "no penalty for two situations, four prohibitions" system to optimize the business environment, while article seventeen establishes a fault-tolerance mechanism [6]. Next Steps - The Changde Municipal People's Congress will submit the "Regulations" to the Provincial People's Congress for approval, after which it will be published and implemented [6]. Upcoming Events - The Fourth Synthetic Biology and Green Manufacturing Conference will be held in Ningbo from August 20-22, focusing on AI and biological manufacturing, with discussions on trends and innovations in the industry [7][9].

Core Insights - Synthetic biology is recognized as the "third biotechnology revolution," following the discovery of the DNA double helix and the Human Genome Project, and is becoming a focal point in global technological competition [1] - It is predicted that 70% of future products will be derived from biological methods [1] Group 1: Industry Developments - Beijing has achieved multiple breakthroughs in synthetic biology manufacturing, with applications in biomedicine, beauty economy, chemical energy, and agriculture [1] - The synthetic biology manufacturing industry in Changping District generated over 6 billion yuan in revenue last year [6] - The Changping District has gathered over 120 synthetic biology companies, with projected revenue exceeding 6 billion yuan in 2024 and fixed asset investments surpassing 4.3 billion yuan [7] Group 2: Company Innovations - Microgen Synthetic, established in December 2021, is one of the earliest teams in China engaged in synthetic biology research and industrialization [3] - The company has developed a one-step fermentation method for producing allulose, achieving over 80% conversion rate and significantly reducing production costs [4] - The company has also established an engineering scale-up center and a small-scale flexible production base in Qinhuangdao, which are now operational [5] Group 3: Technological Advancements - Synthetic biology manufacturing addresses high energy consumption and pollution in chemical production, as well as low efficiency and high costs in agricultural planting [2] - Beijing has made significant advancements in key technologies such as carbon conversion and chassis cell design, leading to innovative products like high-efficiency DNA insertion technology and bio-based adipic acid production [8]

Core Insights - The Beijing pharmaceutical and health industry reached a scale of 1.06 trillion yuan in 2024, with a year-on-year growth of 8.7%, indicating a significant acceleration towards becoming a globally influential modern pharmaceutical and health industry cluster [1] Group 1: Industry Development - The Beijing municipal government has implemented three rounds of action plans since 2018 to accelerate collaborative innovation in the pharmaceutical and health sector, establishing a dual leadership mechanism between technology management and industry management departments [1][2] - In 2024 and 2025, Beijing introduced measures to promote high-quality development in the pharmaceutical sector, attracting eight well-known pharmaceutical companies to establish innovative entities in the city [2] Group 2: Talent and Investment - The city has initiated various talent training programs, including those for physician-scientists and young clinical research talents, to effectively cultivate urgently needed professionals in the industry [2] - A municipal-level investment fund of 20 billion yuan has been established to support innovation and development in the pharmaceutical and health sector [2] Group 3: Technological Advancements - Beijing boasts a concentration of technological resources, including universities and research institutions, which support the design and modification of microorganisms, leading to innovative outcomes in key technology areas [3] - The city has a leading clinical level with numerous national clinical research centers and medical centers, housing expert teams with extensive clinical experience [3] Group 4: Emerging Industries - Significant progress has been made in brain-machine interface and synthetic biology manufacturing, with breakthroughs in key technologies and clinical applications [4][5] - The development of innovative products, such as the world's first efficient large fragment DNA insertion technology and advanced biomanufacturing techniques, has been achieved [5] Group 5: Future Directions - Moving forward, Beijing aims to enhance policy implementation and promote innovation-driven industry development, focusing on brain-machine interfaces and synthetic biology manufacturing to foster new productive forces [6]

Group 1 - The event "Capital Academician Expert Forum" focused on "Synthetic Biology Technology Revolution and Industrial Opportunities," gathering nearly 50 academicians and experts to provide advice for the innovative development of the synthetic biology manufacturing industry in the capital [1] - Keynote speeches were delivered by prominent academicians, sharing research findings to support the transition of agricultural production in the capital towards high-quality and green development [1] - A roundtable discussion addressed current issues and challenges in synthetic biology technology, emphasizing interdisciplinary collaborative innovation and the integration of multiple technologies [1] Group 2 - Synthetic biology technology is a crucial component in accelerating the formation of new productive forces, reshaping production paradigms in agriculture, biology, medicine, energy, and environment [2] - Beijing's promotion of synthetic biology technology innovation has unique advantages in education, technology, talent, and ecology, aiming to closely integrate synthetic biology manufacturing with the cultivation of new bioeconomic dynamics [2] - The "Capital Academician Expert Forum" is organized by the Beijing Talent Work Bureau, the Chinese Academy of Sciences, and the Chinese Academy of Engineering, serving as an important platform for deepening talent integration and technology exchange [2]

Core Viewpoint - Beijing's urban sub-center aims to become an international benchmark for green economy development by focusing on ten green industries and implementing eight major tasks to promote the scale and specialization of green industries by 2027 [1][2]. Group 1: Green Industry Development - The urban sub-center plans to exceed 300 green enterprises and establish one green industry cluster by 2027, enhancing green innovation capabilities and increasing the number of effective green technology patents by approximately 20% annually [2][3]. - The focus will be on developing specialized green industries such as carbon professional services, ESG services, green finance, and synthetic biology manufacturing, while also consolidating existing green industries like renewable energy and smart connected vehicles [3][4]. Group 2: Infrastructure and Investment - The first green industry cluster, the Beijing Green Technology Innovation Service Industrial Park, is under construction and will utilize the old Beijing Optical Instrument Factory site, aiming for completion by the end of 2027 [4][5]. - The park will feature a 100% renewable energy supply system and is expected to reduce annual CO2 emissions by 1,000 tons through advanced energy management systems [4][5]. Group 3: Strategic Initiatives - Key tasks include establishing the Beijing International Green Technology Concept Verification Center, enhancing the role of local industry funds in supporting green economy initiatives, and leveraging the urban sub-center's position as a leading green finance hub [4][5].

Core Viewpoint - The establishment of a new material project in Anxiang County, Hunan, marks a significant step towards developing a non-grain raw material synthetic biology manufacturing industry, with an annual production capacity of 50,000 tons of new materials [1][3]. Group 1: Project Overview - The project focuses on producing cellulose polylactic acid (PLA) using non-grain raw materials such as reeds and straw, which are ideal for bio-manufacturing [3]. - The synthetic biology method will decompose cellulose and hemicellulose from reeds into glucose and xylose, which will then be fermented into lactic acid and polymerized into biodegradable plastics [3]. - The biodegradable plastic produced can decompose completely into carbon dioxide and water within 6 to 12 months after disposal [3]. Group 2: Market and Industry Context - The bio-based raw materials are categorized into grain-based and non-grain-based, with non-grain options like reeds offering significant advantages in cost, energy savings, and carbon reduction compared to grain-based products [3]. - Anxiang County has over 20,000 acres of reeds, primarily located along the Li River, Songzi River, and west of the Hudu River, providing a solid foundation for the synthetic biology industry [3]. - The collaboration with Shanghai Hanhe Biological New Materials Technology Co., Ltd. strengthens Anxiang County's position in the synthetic biology sector [3].

Group 1 - Lingzhu Technology has completed a multi-million yuan angel round financing from Shenzhen Innovation Investment Group and achieved mass production of recombinant spider silk protein, marking a significant milestone in the biobased materials sector [1] - The company utilizes synthetic biology technology to create a new production pathway for spider silk, which is known for its high strength and toughness, surpassing carbon fiber and ballistic materials [2] - Lingzhu Technology has developed a proprietary full-length spider silk gene library, allowing for precise design and regulation of spider silk protein structures to enhance strength, toughness, and biodegradability [2] Group 2 - The company has successfully transitioned from laboratory to factory, achieving stable mass production through microbial fermentation technology and advanced purification and spinning techniques [3] - Lingzhu plans to expand production capacity significantly over the next two years, aiming for larger-scale production by the end of 2026 to meet market demand for high-performance biobased materials [3] - Collaborations with international and domestic brands, as well as partnerships with universities, are in place to develop innovative products based on spider silk protein, covering textiles and skincare [3]